Patent expiry and biosimilars: difference between revisions
Diff·revision 24 → 25·21:29, 27 Feb 2026
Difference between revision 24 and revision 25 of Patent expiry and biosimilars. This revision changed no lines of source — the edit was a null or whitespace change.
| Revision 24 — 15:15, 7 Feb 2026 Peptide_Pete (talk) add the cross-link to the legal-status-by-jurisdiction list 4,553 bytes ±0 | Revision 25 — 21:29, 27 Feb 2026 ImportRecordIna (talk) add the telehealth prescribing point as attributed 4,553 bytes ±0 | ||
|---|---|---|---|
| — | No change to the page source. | — |